Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma

Abe, T.; Minami, K.; Harabayashi, T.; Sazawa, A.; Chiba, H.; Kikuchi, H.; Miyata, H.; Matsumoto, R.; Osawa, T.; Maruyama, S.; IshizakiIshizaki, J.; Mochizuki, T.; Chiba, S.; Akino, T.; Murakumo, M.; Miyajima, N.; Tsuchiya, K.; Murai, S.; Shinohara, N.

Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma

Abe, T.; Minami, K.; Harabayashi, T. et al.

Japanese journal of clinical oncology, 2019, 49(10), 965-971

Permalink : https://hdl.handle.net/2115/76801

このアイテムのアクセス数:607件（2026-10-16 23:40 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1093/jjco/hyz084			31

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/76801
タイトル	Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
著者	Abe, T. ; Minami, K. ; Harabayashi, T. ; Sazawa, A. ; Chiba, H. ; Kikuchi, H. ; Miyata, H. ; Matsumoto, R. ; Osawa, T. ; Maruyama, S. ; IshizakiIshizaki, J. ; Mochizuki, T. ; Chiba, S. ; Akino, T. ; Murakumo, M. ; Miyajima, N. ; Tsuchiya, K. ; Murai, S. ; Shinohara, N.
e-Rad_Researcher 10399842 著者名 Abe, T.
著者名 Minami, K.
著者名 Harabayashi, T.
著者名 Sazawa, A.
著者名 Chiba, H.
著者名 Kikuchi, H.
著者名 Miyata, H.
著者名 Matsumoto, R.
著者名 Osawa, T.
著者名 Maruyama, S.
著者名 IshizakiIshizaki, J.
著者名 Mochizuki, T.
著者名 Chiba, S.
著者名 Akino, T.
著者名 Murakumo, M.
著者名 Miyajima, N.
著者名 Tsuchiya, K.
著者名 Murai, S.
e-Rad_Researcher 90250422 著者名 Shinohara, N.
言語	英語
キーワード	metastatic urothelial carcinoma
	systemic chemotherapy
	maintenance chemotherapy
発行日	2019-10
出版者	Oxford University Press
収録物名	Japanese journal of clinical oncology
巻(号)	49(10)
ページ	965-971
抄録	Objective: Aiming to achieve long-term disease control, maintenance systemic chemotherapy (MSC) with a 1-3-month drug-free interval is continued in selected patients. We report our experience of MSC for metastatic urothelial carcinoma (UC). Methods: Of 228 metastatic UC patients treated with systemic chemotherapy, 40 (17.5%, 40/228) had continuously undergone MSC. Data on the regimen, cycle number, and reason for the discontinuation of MSC were also collected. We analyzed OS from the initiation of MSC until death or the last follow-up, using the log-rank test to assess the significance of differences. Results: The median number of cycles of chemotherapy was 6, and the responses were CR in 6, PR in 20, SD in 13, and PD in 1 before MSC. Gemcitabine plus CDDP or carboplatin was mainly performed as MSC (70%, 28/40). MSC was repeated quarterly in 30 (75%, 30/40), every two months in 8 (20%, 8/40), and with other intervals in 2 (5%, 2/40). Overall, a median of 3.5 cycles (range: 1-29) of MSC was performed. The reason for the discontinuation of MSC was PD in 24 (60%, 24/40), favorable disease control in 9 (22.5%, 9/40), and myelosuppression in 3 (7.5%, 3/40), and for other reasons in 2 (5%, 2/40). MSC was ongoing in 2 (5%, 2/40). The median OS was 27 months from the initiation of MSC. PS0 (P = 0.0169), the absence of lung metastasis (P = 0.0387), and resection of the primary site (P = 0.0495) were associated with long-term survival after MSC. Conclusions: In selected patients, long-term systemic chemotherapy could be performed with a drug-free interval. Our maintenance strategy with cytotoxic drugs may become one of the treatment options for long-term disease control.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	0368-2811
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1093/jjco/hyz084